Harter 2006.
| Methods | RCT Open 2000‐2003 |
|
| Participants | Number: 219 patients (243 episodes) Age: ceftazidime median 57, range (21–70); piperacillin‐tazobactam 53 (19–71) |
|
| Interventions | ceftazidime 2grX3 versus piperacillin‐tazobactam 4.5grX3 |
|
| Outcomes | All‐cause and infection‐related mortality Clinical and microbiological failure Drug modifications Adverse events |
|
| Notes | Germany | |
| Risk of bias | ||
| Bias | Authors' judgement | Support for judgement |
| Adequate sequence generation? | Low risk | Randmization list |
| Allocation concealment? | Low risk | Central in the pharmacy |
| Blinding? All outcomes | High risk | Blinding not used |
| Incomplete outcome data addressed? All‐cause mortality | Unclear risk | Number randomized unclear |
| Incomplete outcome data addressed? Treatment failure | Unclear risk | Number randomized unclear |
| Free of other bias? | High risk | Unit of randomization = episodes; patients to episodes ratio 0.90 |